A Phase 1 interventional study of HRS-8829;Placebo and HRS-8829;Placebo in Acute Ischemia Stroke, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Ischemia with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Ischemia · China.
Among the 39 studies in Ischemia with a site in China, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 38th registered.
545 studies on the registry are indexed under Ischemia; 72 are open to participants now.
Browse Ischemia studies →4 of the 39 studies in Ischemia with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–70
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 30–80
Guangdong Provincial People's Hospital · Sites in China
Ages 18–60 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Ischemia studies recruiting now, 35 (78%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 6 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 74 across 356 interventional studies indexed under Ischemia.
Median enrollment 172 across the 34 interventional studies, 387 across the 5 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Ischemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Ischemia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction(DDI)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-8829;Placebo
Drug: HRS-8829;Placebo
Drug: HRS-8829;Placebo
Drug: HRS-8829;Placebo
Drug: HRS-8829;Edaravone injection
Subject will receive HRS-8829 at dose level 1. Subject will receive placebo at dose level 1.
Subject will receive HRS-8829 at dose level 2. Subject will receive placebo at dose level 2.
Subject will receive HRS-8829 at dose level 3. Subject will receive placebo at dose level 3.
Subject will receive HRS-8829 at dose level 4. Subject will receive placebo at dose level 4.
Drug page: Edaravone
Subject will receive HRS-8829 at dose level 2. Subject will receive edaravone injection at dose level 5.
The incidence and severity of adverse events
Time frame: From ICF signing date to Day8 after single administration
The incidence and severity of adverse events
Time frame: From ICF signing date to Day15 after multiple administrations
The Incidence and severity of adverse events
Time frame: from the date of ICF signing to the 21st day after DDI administration
Maximum observed concentration of HRS-8829 and its metabolite in plasma (Cmax)
Time frame: 0 hour to 48 hour after single administration
Area under the serum concentration time curve (AUC) of HRS-8829 and its metabolite in plasma
Time frame: 0 hour to 48 hour after single administration
Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolite in plasma
Time frame: 0 hour to 48 hour after single administration
Half-life (T1/2) of HRS-8829 and its metabolite in plasma
Time frame: 0 hour to 48 hour after single administration
Clearance (CL) of HRS-8829 and its metabolite in plasma
Time frame: 0 hour to 48 hour after single administration
Volume of distribution (Vz) of HRS-8829 and its metabolite in plasma
Time frame: 0 hour to 48 hour after single administration
Cumulative amount excreted (Ae0-t) of HRS-8829 and its metabolite in urine
Time frame: 0 hour to 48 hour after single administration
Cumulative excretion fraction (Fe0-t) of HRS-8829 and its metabolite in urine
Time frame: 0 hour to 48 hour after single administration
Renal clearance (CLr) of HRS-8829 and its metabolite in urine
Time frame: 0 hour to 48 hour after single administration
Maximum observed concentration at steady-state of HRS-8829 and its metabolite in plasma (Cmax)
Time frame: Day1 to Day15 after multiple administrations
Area under the serum concentration time curve (AUC) at steady-state of HRS-8829 and its metabolite in plasma
Time frame: Day1 to Day15 after multiple administrations
Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolite in plasma
Time frame: Day1 to Day15 after multiple administrations
Half-life (T1/2) of HRS-8829 and its metabolite in plasma
Time frame: Day1 to Day15 after multiple administrations
Clearance (CL) of HRS-8829 and its metabolite in plasma
Time frame: Day1 to Day15 after multiple administrations
Volume of distribution (Vz) of HRS-8829 and its metabolite in plasm
Time frame: Day1 to Day15 after multiple administrations
Maximum observed concentration at steady-state of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day 16 after DDI study single-dose, plasma administrations
Area under the serum concentration time curve (AUC) at steady-state of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Half-life (T1/2) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Clearance (CL) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Volume of distribution (Vz) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Area under the serum concentration time curve (AUC) at steady-state of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Half-life (T1/2) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Volume of distribution (Vz) of HRS-8829 and its metabolites M01 and edaravone
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Jan 2026, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone
Beijing Suncadia Pharmaceuticals Co., Ltd →